ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 1.00 million shares for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2016-11-10
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2016-09-30 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month |
|---|---|---|---|
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | 1.00M shares 10-Q · filed 2016-11-10 | |
| 2016-06-30 | 1.00M shares 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |